Bone cancer Treatment-Olimab 60mg | Blueberrypharma
OLIMAB 60MG
Olimab 60mg injection which attach and repairs only certain cells in the body and help to protect healthy cells from destroy. Olimab 60mg injection is a trade name of denosumab and which belongs to type of monoclonal antibody.This medicine is classified as a “bone-modifying agent”, it works as a RANK ligand (RANKL) inhibitor.
INDICATION OF OLIMAB :
Olimab 60mg dose is indicated for the treatment of Osteoporosis occur in and women (menopause stage) (end of menopause/ change of life), whose have severe problem of fractures increased or who failed to other medication of osteoporosis.
In adults and some adolescents with giant cell tumor of bone which cannot cured with surgery / surgery is not possible is treated with Olimab 60mg injection.
MECHANISM OF ACTION :
Denosumab prohibits RANKL from activating its receptor, RANK, which is on the surface of osteoclasts and their messengers.
Prevention of the RANKL/RANK interplay prevents osteoclast formation, function, and survival, Hence reducing bone resorption and raising bone mass and vitality in both cortical and trabecular bone. Denosumab is decided to target RANKL (RANK ligand), a protein which act as the main signal to help bone removal/resorption. Some of the bone loss conditions, RANKL overcome the body’s natural defense against bone eradication. Without aggregation in Olimab pharmacokinetics with duration was noticed upon multiple dosing of 60 mg SC administered once every 6 months.
PRECAUTIONS :
Olimab injection may improve the negative effects of immuno-suppressants. Especially the risk for severe infections may be raised. Inform your doctor of any immuno-suppressive drugs you early consume.
Prior to start treatment with denosumab, consult with your doctor about any other regimens you are using (including over-the-counter drugs, vitamins, or herbal remedies). Not to take aspirin or products containing aspirin unless your doctor permits this.
Avoid breast feeding during Denosumab treatment.
DRUG – DRUG INTERACTION :
No formal drug-drug interaction with denosumab during trials.
When interacting with some anticancer drug, orthopedic drugs, vaccines will lead to risk of adverse effects can be increased
CONTRAINDICATIONS :
Olimab is contraindicated in :
Hypocalcemia
Pregnancy
Hypersensitivity.
PREGNANCY :
The Olimab belongs to category C which has no sufficient data in pregnant women to convey any medicine analog risk for adverse development outcomes
The medicine in pregnant women is contraindicated for use because it may cause serious risk to the fetus.
MISSED DOSE :
Take the dose immediately before next dose duration. Next dose time reaches then left off the missed dose and continue regular schedule.
Avoid taking double dose at same time.
Please consult the doctor for further information.
FOR MORE INFORMATION :
Call us : +91-97890 77748
Mail to : info@blueberrypharma.com